 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE: ADCT, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates ADCs for patients with hematological malignancies and solid tumors, today announced that the U.S. Food and Drug Administration FDA has accepted its Biologics License Application BLA for loncastuximab tesirine Lonca for the treatment of relapsed or refr 